Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene
Identifieur interne : 002519 ( Istex/Corpus ); précédent : 002518; suivant : 002520Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene
Auteurs : Kees Weijer ; Anita Pfauth ; Rob Van Herwijnen ; Oswald Jarrett ; Rob H. Meloen ; Chris Tomee ; Albert D. M. E. OsterhausSource :
- Vaccine [ 0264-410X ] ; 1993.
English descriptors
- Teeft :
- Adjuvant, Amino acid sequence, Antibody, Antibody response, Antibody responses, Antigenic presentation, Booster, Different peptide elisas, Different peptides, Effective vaccine, Elisa, Empty iscoms, Envelope gene, Epitope, Feline, Feline leukaemia virus, Feline leukemia virus, Felv, Felv elisa, Felv immunization, Felv infection, First experiment, First immunization, Functional activity, Immunization, Immunoblotting, Iscom, Iscoms, Jarrett, Leukaemia, Mabs, Mgpnlv, Microwell plates, Monoclonal antibodies, Myristic acid, Myristylated peptides, Native protein, Natl acad, Negative control, Neutralizing, Neutralizing antibodies, Normal rabbit serum, Nucleotide sequence, Nucleotide sequences, Osterhaus, Other rabbits, Peptide, Peptide antibodies, Peptide combination, Peptide elisas, Peptides iscom, Polyclonal, Polyclonal antibodies, Rabbit, Same binding area, Same conjugates, Same peptides, Second experiment, Subgroup, Synthetic peptides, Tertiary structure, Tertiary structures, Unmyristylated peptides, Vaccine, Variable region, Weijer.
Abstract
Abstract: The surface glycoprotein, gp70, of feline leukaemia virus (FeLV) contains sites which are important in inducing neutralizing antibodies. Using synthetic peptides corresponding to nucleotide sequence 729–957 (amino acid sequence 243–319) of FeLV-A/Glasgow-1, the antigenicity and immunogenicity of this part of the viral surface glycoprotein were investigated. The region contains two highly conserved domains separated by a variable region (VR4), when compared with FeLV of subgroups B and C, and an epitope known to be involved in virus neutralization is located in the N-terminal conserved domain. Five murine monoclonal antibodies generated by immunization with virus were found to be directed to this domain and four were virus-neutralizing. Polyclonal mouse, rabbit and cat anti-FeLV antisera, which were virus-neutralizing, were directed to B-cell epitopes in the peptides. To determine if those synthetic peptides could induce neutralizing antibodies, rabbits were immunized with the peptides, singly or in combination. Antibody responses were measured by ELISA for anti-peptide, anti-FeLV and anti-gp70 activity, by immunoblotting, by membrane immunofluorescence and by virus-neutralization tests. Virus-neutralizing antibodies were induced by FeLV gp70 peptides and there was a synergistic effect on antibody production when a combination of peptides covering amino acid sequence 243–319 of FeLV-A was used. In a second experiment, six rabbits and six cats were immunized with a combination of two peptides, which covered the above-defined FeLV gp70 sequence. Comparisons were made of the responses to these peptides incorporated into immunostimulating complexes (ISCOMs) via myristic acid tails, inoculated with ‘empty’ ISCOMs, or with Al(OH)3. Complete Freund's adjuvant (CFA) had a very strong potentiating effect on the induction of antibodies and immunization with peptides incorporated into ISCOMs was superior to immunization using adjuvants other than CFA. It is very promising that not only in rabbits, but also in the natural host of FeLV, the cat, anti-FeLV gp70 (peptides) antibodies could be induced by FeLV gp70 peptides.
Url:
DOI: 10.1016/0264-410X(93)90384-A
Links to Exploration step
ISTEX:B48880710A6FD88DAC723A1AB9CEAD28FE7CD819Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene</title><author><name sortKey="Weijer, Kees" sort="Weijer, Kees" uniqKey="Weijer K" first="Kees" last="Weijer">Kees Weijer</name><affiliation><mods:affiliation>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Pfauth, Anita" sort="Pfauth, Anita" uniqKey="Pfauth A" first="Anita" last="Pfauth">Anita Pfauth</name><affiliation><mods:affiliation>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Van Herwijnen, Rob" sort="Van Herwijnen, Rob" uniqKey="Van Herwijnen R" first="Rob" last="Van Herwijnen">Rob Van Herwijnen</name><affiliation><mods:affiliation>B.V. European Veterinary Laboratory EVL, Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Jarrett, Oswald" sort="Jarrett, Oswald" uniqKey="Jarrett O" first="Oswald" last="Jarrett">Oswald Jarrett</name><affiliation><mods:affiliation>University of Glasgow, Department of Veterinary Pathology, Glasgow, UK</mods:affiliation></affiliation></author><author><name sortKey="Meloen, Rob H" sort="Meloen, Rob H" uniqKey="Meloen R" first="Rob H." last="Meloen">Rob H. Meloen</name><affiliation><mods:affiliation>Central Veterinary Institute, Lelystad, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Tomee, Chris" sort="Tomee, Chris" uniqKey="Tomee C" first="Chris" last="Tomee">Chris Tomee</name><affiliation><mods:affiliation>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><affiliation><mods:affiliation>The National Institute of Public Health and Environmental Hygiene, Bilthoven, The Netherlands</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B48880710A6FD88DAC723A1AB9CEAD28FE7CD819</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1016/0264-410X(93)90384-A</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-MPKVM6ZH-W/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002519</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002519</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene</title><author><name sortKey="Weijer, Kees" sort="Weijer, Kees" uniqKey="Weijer K" first="Kees" last="Weijer">Kees Weijer</name><affiliation><mods:affiliation>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Pfauth, Anita" sort="Pfauth, Anita" uniqKey="Pfauth A" first="Anita" last="Pfauth">Anita Pfauth</name><affiliation><mods:affiliation>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Van Herwijnen, Rob" sort="Van Herwijnen, Rob" uniqKey="Van Herwijnen R" first="Rob" last="Van Herwijnen">Rob Van Herwijnen</name><affiliation><mods:affiliation>B.V. European Veterinary Laboratory EVL, Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Jarrett, Oswald" sort="Jarrett, Oswald" uniqKey="Jarrett O" first="Oswald" last="Jarrett">Oswald Jarrett</name><affiliation><mods:affiliation>University of Glasgow, Department of Veterinary Pathology, Glasgow, UK</mods:affiliation></affiliation></author><author><name sortKey="Meloen, Rob H" sort="Meloen, Rob H" uniqKey="Meloen R" first="Rob H." last="Meloen">Rob H. Meloen</name><affiliation><mods:affiliation>Central Veterinary Institute, Lelystad, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Tomee, Chris" sort="Tomee, Chris" uniqKey="Tomee C" first="Chris" last="Tomee">Chris Tomee</name><affiliation><mods:affiliation>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><affiliation><mods:affiliation>The National Institute of Public Health and Environmental Hygiene, Bilthoven, The Netherlands</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1993">1993</date><biblScope unit="volume">11</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="946">946</biblScope><biblScope unit="page" to="956">956</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adjuvant</term><term>Amino acid sequence</term><term>Antibody</term><term>Antibody response</term><term>Antibody responses</term><term>Antigenic presentation</term><term>Booster</term><term>Different peptide elisas</term><term>Different peptides</term><term>Effective vaccine</term><term>Elisa</term><term>Empty iscoms</term><term>Envelope gene</term><term>Epitope</term><term>Feline</term><term>Feline leukaemia virus</term><term>Feline leukemia virus</term><term>Felv</term><term>Felv elisa</term><term>Felv immunization</term><term>Felv infection</term><term>First experiment</term><term>First immunization</term><term>Functional activity</term><term>Immunization</term><term>Immunoblotting</term><term>Iscom</term><term>Iscoms</term><term>Jarrett</term><term>Leukaemia</term><term>Mabs</term><term>Mgpnlv</term><term>Microwell plates</term><term>Monoclonal antibodies</term><term>Myristic acid</term><term>Myristylated peptides</term><term>Native protein</term><term>Natl acad</term><term>Negative control</term><term>Neutralizing</term><term>Neutralizing antibodies</term><term>Normal rabbit serum</term><term>Nucleotide sequence</term><term>Nucleotide sequences</term><term>Osterhaus</term><term>Other rabbits</term><term>Peptide</term><term>Peptide antibodies</term><term>Peptide combination</term><term>Peptide elisas</term><term>Peptides iscom</term><term>Polyclonal</term><term>Polyclonal antibodies</term><term>Rabbit</term><term>Same binding area</term><term>Same conjugates</term><term>Same peptides</term><term>Second experiment</term><term>Subgroup</term><term>Synthetic peptides</term><term>Tertiary structure</term><term>Tertiary structures</term><term>Unmyristylated peptides</term><term>Vaccine</term><term>Variable region</term><term>Weijer</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The surface glycoprotein, gp70, of feline leukaemia virus (FeLV) contains sites which are important in inducing neutralizing antibodies. Using synthetic peptides corresponding to nucleotide sequence 729–957 (amino acid sequence 243–319) of FeLV-A/Glasgow-1, the antigenicity and immunogenicity of this part of the viral surface glycoprotein were investigated. The region contains two highly conserved domains separated by a variable region (VR4), when compared with FeLV of subgroups B and C, and an epitope known to be involved in virus neutralization is located in the N-terminal conserved domain. Five murine monoclonal antibodies generated by immunization with virus were found to be directed to this domain and four were virus-neutralizing. Polyclonal mouse, rabbit and cat anti-FeLV antisera, which were virus-neutralizing, were directed to B-cell epitopes in the peptides. To determine if those synthetic peptides could induce neutralizing antibodies, rabbits were immunized with the peptides, singly or in combination. Antibody responses were measured by ELISA for anti-peptide, anti-FeLV and anti-gp70 activity, by immunoblotting, by membrane immunofluorescence and by virus-neutralization tests. Virus-neutralizing antibodies were induced by FeLV gp70 peptides and there was a synergistic effect on antibody production when a combination of peptides covering amino acid sequence 243–319 of FeLV-A was used. In a second experiment, six rabbits and six cats were immunized with a combination of two peptides, which covered the above-defined FeLV gp70 sequence. Comparisons were made of the responses to these peptides incorporated into immunostimulating complexes (ISCOMs) via myristic acid tails, inoculated with ‘empty’ ISCOMs, or with Al(OH)3. Complete Freund's adjuvant (CFA) had a very strong potentiating effect on the induction of antibodies and immunization with peptides incorporated into ISCOMs was superior to immunization using adjuvants other than CFA. It is very promising that not only in rabbits, but also in the natural host of FeLV, the cat, anti-FeLV gp70 (peptides) antibodies could be induced by FeLV gp70 peptides.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>peptide</json:string><json:string>felv</json:string><json:string>elisa</json:string><json:string>iscom</json:string><json:string>mabs</json:string><json:string>epitope</json:string><json:string>iscoms</json:string><json:string>leukaemia</json:string><json:string>neutralizing</json:string><json:string>weijer</json:string><json:string>adjuvant</json:string><json:string>immunization</json:string><json:string>subgroup</json:string><json:string>synthetic peptides</json:string><json:string>jarrett</json:string><json:string>immunoblotting</json:string><json:string>vaccine</json:string><json:string>polyclonal</json:string><json:string>peptide combination</json:string><json:string>felv elisa</json:string><json:string>osterhaus</json:string><json:string>same peptides</json:string><json:string>different peptide elisas</json:string><json:string>different peptides</json:string><json:string>mgpnlv</json:string><json:string>polyclonal antibodies</json:string><json:string>feline leukaemia virus</json:string><json:string>antibody response</json:string><json:string>neutralizing antibodies</json:string><json:string>second experiment</json:string><json:string>peptide elisas</json:string><json:string>empty iscoms</json:string><json:string>first experiment</json:string><json:string>feline</json:string><json:string>other rabbits</json:string><json:string>rabbit</json:string><json:string>booster</json:string><json:string>antibody</json:string><json:string>native protein</json:string><json:string>envelope gene</json:string><json:string>felv immunization</json:string><json:string>felv infection</json:string><json:string>negative control</json:string><json:string>nucleotide sequence</json:string><json:string>antibody responses</json:string><json:string>monoclonal antibodies</json:string><json:string>effective vaccine</json:string><json:string>amino acid sequence</json:string><json:string>first immunization</json:string><json:string>microwell plates</json:string><json:string>same conjugates</json:string><json:string>same binding area</json:string><json:string>antigenic presentation</json:string><json:string>variable region</json:string><json:string>tertiary structure</json:string><json:string>feline leukemia virus</json:string><json:string>normal rabbit serum</json:string><json:string>myristic acid</json:string><json:string>myristylated peptides</json:string><json:string>functional activity</json:string><json:string>peptides iscom</json:string><json:string>peptide antibodies</json:string><json:string>tertiary structures</json:string><json:string>unmyristylated peptides</json:string><json:string>natl acad</json:string><json:string>nucleotide sequences</json:string></teeft></keywords><author><json:item><name>Kees Weijer</name><affiliations><json:string>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</json:string></affiliations></json:item><json:item><name>Anita Pfauth</name><affiliations><json:string>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</json:string></affiliations></json:item><json:item><name>Rob van Herwijnen</name><affiliations><json:string>B.V. European Veterinary Laboratory EVL, Amsterdam, The Netherlands</json:string></affiliations></json:item><json:item><name>Oswald Jarrett</name><affiliations><json:string>University of Glasgow, Department of Veterinary Pathology, Glasgow, UK</json:string></affiliations></json:item><json:item><name>Rob H. Meloen</name><affiliations><json:string>Central Veterinary Institute, Lelystad, The Netherlands</json:string></affiliations></json:item><json:item><name>Chris Tomee</name><affiliations><json:string>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</json:string></affiliations></json:item><json:item><name>Albert D.M.E. Osterhaus</name><affiliations><json:string>The National Institute of Public Health and Environmental Hygiene, Bilthoven, The Netherlands</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Feline leukaemia virus gp70</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>peptide</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ISCOM</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ELISA</value></json:item></subject><arkIstex>ark:/67375/6H6-MPKVM6ZH-W</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Short communication</json:string></originalGenre><abstract>Abstract: The surface glycoprotein, gp70, of feline leukaemia virus (FeLV) contains sites which are important in inducing neutralizing antibodies. Using synthetic peptides corresponding to nucleotide sequence 729–957 (amino acid sequence 243–319) of FeLV-A/Glasgow-1, the antigenicity and immunogenicity of this part of the viral surface glycoprotein were investigated. The region contains two highly conserved domains separated by a variable region (VR4), when compared with FeLV of subgroups B and C, and an epitope known to be involved in virus neutralization is located in the N-terminal conserved domain. Five murine monoclonal antibodies generated by immunization with virus were found to be directed to this domain and four were virus-neutralizing. Polyclonal mouse, rabbit and cat anti-FeLV antisera, which were virus-neutralizing, were directed to B-cell epitopes in the peptides. To determine if those synthetic peptides could induce neutralizing antibodies, rabbits were immunized with the peptides, singly or in combination. Antibody responses were measured by ELISA for anti-peptide, anti-FeLV and anti-gp70 activity, by immunoblotting, by membrane immunofluorescence and by virus-neutralization tests. Virus-neutralizing antibodies were induced by FeLV gp70 peptides and there was a synergistic effect on antibody production when a combination of peptides covering amino acid sequence 243–319 of FeLV-A was used. In a second experiment, six rabbits and six cats were immunized with a combination of two peptides, which covered the above-defined FeLV gp70 sequence. Comparisons were made of the responses to these peptides incorporated into immunostimulating complexes (ISCOMs) via myristic acid tails, inoculated with ‘empty’ ISCOMs, or with Al(OH)3. Complete Freund's adjuvant (CFA) had a very strong potentiating effect on the induction of antibodies and immunization with peptides incorporated into ISCOMs was superior to immunization using adjuvants other than CFA. It is very promising that not only in rabbits, but also in the natural host of FeLV, the cat, anti-FeLV gp70 (peptides) antibodies could be induced by FeLV gp70 peptides.</abstract><qualityIndicators><score>10</score><pdfWordCount>7715</pdfWordCount><pdfCharCount>44196</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>11</pdfPageCount><pdfPageSize>591 x 843 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>307</abstractWordCount><abstractCharCount>2154</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene</title><pmid><json:string>7692683</json:string></pmid><pii><json:string>0264-410X(93)90384-A</json:string></pii><genre><json:string>brief-communication</json:string></genre><serie><title>A virus-like particle associated with leukaemia/lymphosarcoma</title><language><json:string>unknown</json:string></language><pages><first>567</first></pages></serie><host><title>Vaccine</title><language><json:string>unknown</json:string></language><publicationDate>1993</publicationDate><issn><json:string>0264-410X</json:string></issn><pii><json:string>S0264-410X(00)X0156-9</json:string></pii><volume>11</volume><issue>9</issue><pages><first>946</first><last>956</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>6-9-21</json:string><json:string>1993</json:string><json:string>8-9-21</json:string><json:string>11-11-12</json:string><json:string>3000</json:string><json:string>17 and 6-15</json:string><json:string>3-3-18</json:string></date><geogName></geogName><orgName><json:string>Butterworth-Heinemann Ltd</json:string><json:string>European Veterinary Laboratory EVL, Amsterdam, The Netherlands</json:string><json:string>National Institute of Public Health and Environmental Hygiene</json:string><json:string>University of Glasgow</json:string><json:string>New Zealand White</json:string><json:string>Central Veterinary Institute, Lelystad, The Netherlands</json:string><json:string>Department of Veterinary Pathology, Glasgow, UK</json:string><json:string>Division of Immunology</json:string><json:string>Amsterdam</json:string><json:string>Netherlands</json:string><json:string>European Veterinary Laboratory</json:string></orgName><orgName_funder><json:string>Amsterdam</json:string><json:string>Netherlands</json:string><json:string>European Veterinary Laboratory</json:string></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Oswald Jarrett</json:string><json:string>K. Weijer</json:string><json:string>Antoni van Leeuwenhoek</json:string><json:string>D.M.E. Osterhaus</json:string><json:string>Anita Pfauth</json:string><json:string>H. Meloen</json:string><json:string>Chris Tomee</json:string></persName><placeName><json:string>Washington</json:string><json:string>DC</json:string><json:string>Amsterdam</json:string><json:string>Glasgow</json:string><json:string>MA</json:string><json:string>Cambridge</json:string><json:string>Netherlands</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Akerblom et al.</json:string><json:string>Elder et al.</json:string><json:string>K. Weijer et al.</json:string><json:string>Nunberg et al.</json:string><json:string>Towbin et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-MPKVM6ZH-W</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - medicine, research & experimental</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Public Health, Environmental and Occupational Health</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Veterinary</json:string><json:string>3 - General Veterinary</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - General Immunology and Microbiology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Molecular Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences biologiques fondamentales et appliquees. psychologie</json:string><json:string>4 - microbiologie</json:string></inist></categories><publicationDate>1993</publicationDate><copyrightDate>1993</copyrightDate><doi><json:string>10.1016/0264-410X(93)90384-A</json:string></doi><id>B48880710A6FD88DAC723A1AB9CEAD28FE7CD819</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-MPKVM6ZH-W/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-MPKVM6ZH-W/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-MPKVM6ZH-W/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1993</date></publicationStmt><notesStmt><note type="brief-communication" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-S9SX2MFS-0">brief-communication</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note type="content">Section title: Paper</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene</title><author xml:id="author-0000"><persName><forename type="first">Kees</forename><surname>Weijer</surname></persName><affiliation>To whom correspondence should be addressed.</affiliation><affiliation>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Anita</forename><surname>Pfauth</surname></persName><affiliation>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Rob</forename><surname>van Herwijnen</surname></persName><affiliation>B.V. European Veterinary Laboratory EVL, Amsterdam, The Netherlands</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Oswald</forename><surname>Jarrett</surname></persName><affiliation>University of Glasgow, Department of Veterinary Pathology, Glasgow, UK</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Rob H.</forename><surname>Meloen</surname></persName><affiliation>Central Veterinary Institute, Lelystad, The Netherlands</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Chris</forename><surname>Tomee</surname></persName><affiliation>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Albert D.M.E.</forename><surname>Osterhaus</surname></persName><affiliation>The National Institute of Public Health and Environmental Hygiene, Bilthoven, The Netherlands</affiliation></author><idno type="istex">B48880710A6FD88DAC723A1AB9CEAD28FE7CD819</idno><idno type="ark">ark:/67375/6H6-MPKVM6ZH-W</idno><idno type="DOI">10.1016/0264-410X(93)90384-A</idno><idno type="PII">0264-410X(93)90384-A</idno></analytic><monogr><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="pISSN">0264-410X</idno><idno type="PII">S0264-410X(00)X0156-9</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1993"></date><biblScope unit="volume">11</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="946">946</biblScope><biblScope unit="page" to="956">956</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1993</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: The surface glycoprotein, gp70, of feline leukaemia virus (FeLV) contains sites which are important in inducing neutralizing antibodies. Using synthetic peptides corresponding to nucleotide sequence 729–957 (amino acid sequence 243–319) of FeLV-A/Glasgow-1, the antigenicity and immunogenicity of this part of the viral surface glycoprotein were investigated. The region contains two highly conserved domains separated by a variable region (VR4), when compared with FeLV of subgroups B and C, and an epitope known to be involved in virus neutralization is located in the N-terminal conserved domain. Five murine monoclonal antibodies generated by immunization with virus were found to be directed to this domain and four were virus-neutralizing. Polyclonal mouse, rabbit and cat anti-FeLV antisera, which were virus-neutralizing, were directed to B-cell epitopes in the peptides. To determine if those synthetic peptides could induce neutralizing antibodies, rabbits were immunized with the peptides, singly or in combination. Antibody responses were measured by ELISA for anti-peptide, anti-FeLV and anti-gp70 activity, by immunoblotting, by membrane immunofluorescence and by virus-neutralization tests. Virus-neutralizing antibodies were induced by FeLV gp70 peptides and there was a synergistic effect on antibody production when a combination of peptides covering amino acid sequence 243–319 of FeLV-A was used. In a second experiment, six rabbits and six cats were immunized with a combination of two peptides, which covered the above-defined FeLV gp70 sequence. Comparisons were made of the responses to these peptides incorporated into immunostimulating complexes (ISCOMs) via myristic acid tails, inoculated with ‘empty’ ISCOMs, or with Al(OH)3. Complete Freund's adjuvant (CFA) had a very strong potentiating effect on the induction of antibodies and immunization with peptides incorporated into ISCOMs was superior to immunization using adjuvants other than CFA. It is very promising that not only in rabbits, but also in the natural host of FeLV, the cat, anti-FeLV gp70 (peptides) antibodies could be induced by FeLV gp70 peptides.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Feline leukaemia virus gp70</term></item><item><term>peptide</term></item><item><term>ISCOM</term></item><item><term>ELISA</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1992-08-10">Modified</change><change when="1993">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-MPKVM6ZH-W/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="sco"><item-info><jid>JVAC</jid><aid>9390384A</aid><ce:pii>0264-410X(93)90384-A</ce:pii><ce:doi>10.1016/0264-410X(93)90384-A</ce:doi><ce:copyright type="unknown" year="1993"></ce:copyright></item-info><head><ce:dochead><ce:textfn>Paper</ce:textfn></ce:dochead><ce:title>Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV <ce:italic>env</ce:italic> gene</ce:title><ce:author-group><ce:author><ce:given-name>Kees</ce:given-name><ce:surname>Weijer</ce:surname><ce:cross-ref refid="COR1"><ce:sup>∞</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup>†</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Anita</ce:given-name><ce:surname>Pfauth</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Rob</ce:given-name><ce:surname>van Herwijnen</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>†</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Oswald</ce:given-name><ce:surname>Jarrett</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>‡</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Rob H.</ce:given-name><ce:surname>Meloen</ce:surname><ce:cross-ref refid="AFF4"><ce:sup>§</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Chris</ce:given-name><ce:surname>Tomee</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Albert D.M.E.</ce:given-name><ce:surname>Osterhaus</ce:surname><ce:cross-ref refid="AFF5"><ce:sup>∥</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>∗</ce:label><ce:textfn>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>†</ce:label><ce:textfn>B.V. European Veterinary Laboratory EVL, Amsterdam, The Netherlands</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>‡</ce:label><ce:textfn>University of Glasgow, Department of Veterinary Pathology, Glasgow, UK</ce:textfn></ce:affiliation><ce:affiliation id="AFF4"><ce:label>§</ce:label><ce:textfn>Central Veterinary Institute, Lelystad, The Netherlands</ce:textfn></ce:affiliation><ce:affiliation id="AFF5"><ce:label>∥</ce:label><ce:textfn>The National Institute of Public Health and Environmental Hygiene, Bilthoven, The Netherlands</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∞</ce:label><ce:text>To whom correspondence should be addressed.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="22" month="5" year="1992"></ce:date-received><ce:date-revised day="10" month="8" year="1992"></ce:date-revised><ce:date-accepted day="25" month="9" year="1992"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>The surface glycoprotein, gp70, of feline leukaemia virus (FeLV) contains sites which are important in inducing neutralizing antibodies. Using synthetic peptides corresponding to nucleotide sequence 729–957 (amino acid sequence 243–319) of FeLV-A/Glasgow-1, the antigenicity and immunogenicity of this part of the viral surface glycoprotein were investigated. The region contains two highly conserved domains separated by a variable region (VR4), when compared with FeLV of subgroups B and C, and an epitope known to be involved in virus neutralization is located in the <ce:italic>N</ce:italic>-terminal conserved domain. Five murine monoclonal antibodies generated by immunization with virus were found to be directed to this domain and four were virus-neutralizing. Polyclonal mouse, rabbit and cat anti-FeLV antisera, which were virus-neutralizing, were directed to B-cell epitopes in the peptides. To determine if those synthetic peptides could induce neutralizing antibodies, rabbits were immunized with the peptides, singly or in combination. Antibody responses were measured by ELISA for anti-peptide, anti-FeLV and anti-gp70 activity, by immunoblotting, by membrane immunofluorescence and by virus-neutralization tests. Virus-neutralizing antibodies were induced by FeLV gp70 peptides and there was a synergistic effect on antibody production when a combination of peptides covering amino acid sequence 243–319 of FeLV-A was used. In a second experiment, six rabbits and six cats were immunized with a combination of two peptides, which covered the above-defined FeLV gp70 sequence. Comparisons were made of the responses to these peptides incorporated into immunostimulating complexes (ISCOMs) via myristic acid tails, inoculated with ‘empty’ ISCOMs, or with Al(OH)<ce:inf>3</ce:inf>. Complete Freund's adjuvant (CFA) had a very strong potentiating effect on the induction of antibodies and immunization with peptides incorporated into ISCOMs was superior to immunization using adjuvants other than CFA. It is very promising that not only in rabbits, but also in the natural host of FeLV, the cat, anti-FeLV gp70 (peptides) antibodies could be induced by FeLV gp70 peptides.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Feline leukaemia virus gp70</ce:text></ce:keyword><ce:keyword><ce:text>peptide</ce:text></ce:keyword><ce:keyword><ce:text>ISCOM</ce:text></ce:keyword><ce:keyword><ce:text>ELISA</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV</title></titleInfo><name type="personal"><namePart type="given">Kees</namePart><namePart type="family">Weijer</namePart><affiliation>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</affiliation><description>To whom correspondence should be addressed.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anita</namePart><namePart type="family">Pfauth</namePart><affiliation>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rob</namePart><namePart type="family">van Herwijnen</namePart><affiliation>B.V. European Veterinary Laboratory EVL, Amsterdam, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Oswald</namePart><namePart type="family">Jarrett</namePart><affiliation>University of Glasgow, Department of Veterinary Pathology, Glasgow, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rob H.</namePart><namePart type="family">Meloen</namePart><affiliation>Central Veterinary Institute, Lelystad, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chris</namePart><namePart type="family">Tomee</namePart><affiliation>The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Division of Immunology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Albert D.M.E.</namePart><namePart type="family">Osterhaus</namePart><affiliation>The National Institute of Public Health and Environmental Hygiene, Bilthoven, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="brief-communication" displayLabel="Short communication" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-S9SX2MFS-0">brief-communication</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1993</dateIssued><dateModified encoding="w3cdtf">1992-08-10</dateModified><copyrightDate encoding="w3cdtf">1993</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: The surface glycoprotein, gp70, of feline leukaemia virus (FeLV) contains sites which are important in inducing neutralizing antibodies. Using synthetic peptides corresponding to nucleotide sequence 729–957 (amino acid sequence 243–319) of FeLV-A/Glasgow-1, the antigenicity and immunogenicity of this part of the viral surface glycoprotein were investigated. The region contains two highly conserved domains separated by a variable region (VR4), when compared with FeLV of subgroups B and C, and an epitope known to be involved in virus neutralization is located in the N-terminal conserved domain. Five murine monoclonal antibodies generated by immunization with virus were found to be directed to this domain and four were virus-neutralizing. Polyclonal mouse, rabbit and cat anti-FeLV antisera, which were virus-neutralizing, were directed to B-cell epitopes in the peptides. To determine if those synthetic peptides could induce neutralizing antibodies, rabbits were immunized with the peptides, singly or in combination. Antibody responses were measured by ELISA for anti-peptide, anti-FeLV and anti-gp70 activity, by immunoblotting, by membrane immunofluorescence and by virus-neutralization tests. Virus-neutralizing antibodies were induced by FeLV gp70 peptides and there was a synergistic effect on antibody production when a combination of peptides covering amino acid sequence 243–319 of FeLV-A was used. In a second experiment, six rabbits and six cats were immunized with a combination of two peptides, which covered the above-defined FeLV gp70 sequence. Comparisons were made of the responses to these peptides incorporated into immunostimulating complexes (ISCOMs) via myristic acid tails, inoculated with ‘empty’ ISCOMs, or with Al(OH)3. Complete Freund's adjuvant (CFA) had a very strong potentiating effect on the induction of antibodies and immunization with peptides incorporated into ISCOMs was superior to immunization using adjuvants other than CFA. It is very promising that not only in rabbits, but also in the natural host of FeLV, the cat, anti-FeLV gp70 (peptides) antibodies could be induced by FeLV gp70 peptides.</abstract><note type="content">Section title: Paper</note><subject><genre>Keywords</genre><topic>Feline leukaemia virus gp70</topic><topic>peptide</topic><topic>ISCOM</topic><topic>ELISA</topic></subject><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><titleInfo type="abbreviated"><title>JVAC</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1993</dateIssued></originInfo><identifier type="ISSN">0264-410X</identifier><identifier type="PII">S0264-410X(00)X0156-9</identifier><part><date>1993</date><detail type="volume"><number>11</number><caption>vol.</caption></detail><detail type="issue"><number>9</number><caption>no.</caption></detail><extent unit="issue-pages"><start>883</start><end>984</end></extent><extent unit="pages"><start>946</start><end>956</end></extent></part></relatedItem><identifier type="istex">B48880710A6FD88DAC723A1AB9CEAD28FE7CD819</identifier><identifier type="ark">ark:/67375/6H6-MPKVM6ZH-W</identifier><identifier type="DOI">10.1016/0264-410X(93)90384-A</identifier><identifier type="PII">0264-410X(93)90384-A</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-MPKVM6ZH-W/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002519 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002519 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:B48880710A6FD88DAC723A1AB9CEAD28FE7CD819
|texte= Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene
}}
| This area was generated with Dilib version V0.6.33. |  |